Mengmeng Li,Rongshou Zheng,Luigino Dal Maso et al.
Mengmeng Li et al.
Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials [0.03%]
甲状腺相关眼病活动期患者 teprotumumab 治疗的汇总数据分析、亚组分析及停药后随访结果：两项随机、双盲、安慰剂对照、多中心试验
George J Kahaly,Raymond S Douglas,Robert J Holt et al.
George J Kahaly et al.
Background: Thyroid eye disease manifests inflammation and treatment-resistant proptosis and diplopia. Teprotumumab, an insulin-like growth factor-1 receptor inhibiting monoclonal antibody, was approved in the USA on Jan ...
Randomized Controlled Trial
The lancet. Diabetes & endocrinology. 2021 Jun;9(6):360-372. DOI:10.1016/S2213-8587(21)00056-5 2021
Towards unified and impactful policies to reduce ultra-processed food consumption and promote healthier eating [0.03%]
减少超加工食品消费和促进更健康饮食的统一且具影响力的政策研究
Barry M Popkin,Simon Barquera,Camila Corvalan et al.
Barry M Popkin et al.
The global surges in obesity and nutrition-related non-communicable diseases (NCDs) have created a need for decisive new food policy initiatives. A major concern has been the impact of ultra-processed foods (UPFs) and ultra-processed drinks...
The knowns and unknowns of teprotumumab for thyroid eye disease [0.03%]
.teprotumumab治疗甲状腺眼病的已知与未知事项
Tomasz Bednarczuk,Simon H Pearce
Tomasz Bednarczuk
Post-exercise recovery for the endurance athlete with type 1 diabetes: a consensus statement [0.03%]
1 型糖尿病耐力运动员运动后的恢复：共识声明
Sam N Scott,Federico Y Fontana,Matt Cocks et al.
Sam N Scott et al.
There has been substantial progress in the knowledge of exercise and type 1 diabetes, with the development of guidelines for optimal glucose management. In addition, an increasing number of people living with type 1 diabetes are pushing the...
Jesper Jensen,Massar Omar,Jacob Eifer Møller et al.
Jesper Jensen et al.
Panagiota Anyfanti,Erasmia Sampani,Apostolos Tsapas
Panagiota Anyfanti
Atsushi Tanaka,Koichi Node
Atsushi Tanaka
Semaglutide for obesity: four STEPs forward, but more to come [0.03%]
塞马グルテペプチド的肥胖治疗适应证获批：四步成功，但仍需更多工作
Donna H Ryan
Donna H Ryan